In a groundbreaking partnership, Unilabs and C2N Diagnostics are collaborating to enhance brain health diagnostics and research in Europe and globally. This multi-year agreement grants Unilabs exclusive access to C2N’s Precivity portfolio of blood tests in Europe, including Norway, Switzerland, the United Kingdom, Peru, Saudi Arabia, and the United Arab Emirates.
C2N’s Precivity blood tests detect amyloid plaques and neurofibrillary tangles in the brain, pathological hallmarks of Alzheimer’s disease. These tests support the diagnosis of Alzheimer’s and guide treatment decisions based on the underlying dementia causes.
Unilabs plans to establish a European testing network to perform Precivity tests at healthcare institutions. This ensures consistent and accurate testing comparable to the quality provided at C2N’s central laboratory in St. Louis, Missouri.
The partnership leverages C2N’s proprietary biomarker pipeline, Unilabs’ innovation, and global reach. Together, they aim to revolutionize early diagnosis, research, and long-term outcomes for patients with cognitive concerns or those at risk of Alzheimer’s.
Unilabs Head of Innovation, Dr. Rahul Chaudhary, emphasizes the need for less invasive and accessible diagnostic procedures for Alzheimer’s patients. This partnership addresses this unmet need and transforms the diagnostic experience for patients seeking personalized medicine tools.
The collaboration supports healthcare providers and researchers in identifying Alzheimer’s early, informing treatment decisions, and facilitating disease prevention strategies. Unilabs is committed to leveraging these innovations to improve patient outcomes and maximize life.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
